Quality of Life Measurement in Treatment Naïve Patients With HCV Genotype 1 Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®) (HEMATITE)

                                                                                                                                                                                                                 

Study description

This is an observational, prospective, open-label, single-arm, multicenter, real-life study designed to observe the impact of paritaprevir/ritonavir/ombitasvir with dasabuvir regimen (Viekirax®/Exviera®, 3D regimen) on total daytime physical activity and fatigue in participants with Hepatitis C Virus (HCV) genotype 1 (GT1).

Pathology

Hepatitis C Virus HCV

Study type

Post-marketing observation study

Status

Terminated

Study start date

2017

Study completion date

2018

Funder Type

Industry funded study

Investigator

Dr. med. Lorenzo MAGENTA

Recruitment

Completed

Learn more